Makeover sees Viatris move further away from generics
The speciality group will soon be without biosimilars; in the meantime it's buying two companies with patent-protected medicines.
Takeover-driven resurgence fails to materialise for biotech
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
